AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment ...

Pharmaceutical stocks are getting more attention these days as the global drug market is expected to reach $1.21 trillion in ...

A key trading signal flashed for AbbVie shares at a price of $228.47, after which ABBV rose as much as 2.4% to an intraday ...

AbbVie Inc. (NYSE: ABBV) delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an ...

AbbVie offers a strong bullish outlook with rising earnings, dividends, and technical signals. Read here for an analysis of ...

For its third quarter, AbbVie reaped just under $15.78 billion in revenue, which was 9% higher on a year-over-year basis. This was led by the company's enviable collection of blockbuster drugs; ...

AbbVie ABBV stock has risen 30.7% in the past six months compared with an increase of 8.9% for the industry. The stock has ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter ...

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...